Singh Kuldeep, Juneja Amandeep, Bajaj Tushar, Voto Christian, Schor Jonathan, Zia Saqib, Deitch Jonathan
Staten Island University Hospital, Staten Island, NY, USA.
Kern Medical Center, Bakersfield, CA, USA.
Vasc Endovascular Surg. 2020 Jul;54(5):430-435. doi: 10.1177/1538574420925586.
Cadaveric saphenous vein (CV) conduits are used in rare instances for limb salvage in patients without autogenous veins although long-term outcome data are scarce. This study was designed to evaluate the outcomes of CV bypass in patients with threatened limbs.
We retrospectively reviewed the charts from 2010 to 2017 of 25 patients who underwent 30 CV allografts for critical limb ischemia and acute limb ischemia. Patient charts were reviewed for demographics, comorbidities, smoking status, indications for bypass, and outcomes. Primary outcomes included graft patency, major amputation rates, and mortality. Secondary outcomes measured included infection rates, 30-day major adverse cardiac events (MACE) and major adverse limb events (MALE). Statistical analysis was performed using time series and Kaplan-Meier survival curves.
A total of 30 limbs received CV lower extremity bypasses (20 males, 10 female), and the average age was 68 ± 4 years. Primary patency rates were 71%, 42%, and 28% at 3, 6, and 12 months, respectively. Assisted primary patency rates were 78%, 56%, and 37% at 3, 6, and 12 months, respectively. Secondary patency rates were 77%, 59%, and 28% at 3, 6, and 12 months, respectively. Minor amputations, defined as amputations below the transmetatarsal level occurred in 5 (20%) patients. Wound infection occurred in 8 (32%) patients which was managed with local wound care and no patients required an extraanatomic bypass for limb salvage. Thirty-day MALE occurred in 7 (23.3%) patients. We had no 30-day mortality or MACE. The average graft length was 64.2 ± 8 cm with an average graft diameter of 3.9 ± 2 mm. Amputation-free survival and overall survival at 12 months were 20 (68%) and 21 (84%), respectively.
Cadaveric saphenous vein allograft may be used as a bypass conduit as a viable surgical option before limb amputation. Despite the poor patency rates, the limb salvage rates of cadaveric vein grafts demonstrate that this alternate conduit may be considered when no autogenous vein is available.
在没有自体静脉的患者中,尸体隐静脉(CV)导管在肢体挽救的罕见情况下使用,尽管长期结果数据稀缺。本研究旨在评估CV旁路手术在肢体受到威胁的患者中的结果。
我们回顾性分析了2010年至2017年期间25例接受30次CV同种异体移植治疗严重肢体缺血和急性肢体缺血患者的病历。对患者病历进行人口统计学、合并症、吸烟状况、旁路手术指征和结果的评估。主要结果包括移植物通畅率、大截肢率和死亡率。测量的次要结果包括感染率、30天主要不良心脏事件(MACE)和主要不良肢体事件(MALE)。使用时间序列和Kaplan-Meier生存曲线进行统计分析。
共有30条肢体接受了CV下肢旁路手术(20例男性,10例女性),平均年龄为68±4岁。3个月、6个月和12个月时的初次通畅率分别为71%、42%和28%。辅助初次通畅率在3个月、6个月和12个月时分别为78%、56%和37%。3个月、6个月和12个月时的二次通畅率分别为77%、59%和28%。5例(20%)患者发生了定义为经跖骨水平以下截肢的小截肢。8例(32%)患者发生伤口感染,通过局部伤口护理进行处理,没有患者需要进行解剖外旁路手术来挽救肢体。7例(23.3%)患者发生了30天MALE。我们没有30天死亡率或MACE。平均移植物长度为64.2±8 cm,平均移植物直径为3.9±2 mm。12个月时的无截肢生存率和总生存率分别为20例(68%)和21例(84%)。
尸体隐静脉同种异体移植可作为旁路导管,是肢体截肢前可行的手术选择。尽管通畅率较低,但尸体静脉移植物的肢体挽救率表明,在没有自体静脉可用时可考虑这种替代导管。